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SUMMARY
Sleep problems in children are associated with poor health, behavioural
and cognitive problems, as are deﬁciencies of long-chain omega-3 fatty
acids such as docosahexaenoic acid. Theory and some evidence support
a role for these fatty acids in sleep regulation, but this issue has received
little formal investigation. We examined associations between blood fatty
acid concentrations (from ﬁngerstick blood samples) and subjective sleep
(using an age-standardized parent questionnaire) in a large epidemiolog-
ical sample of healthy children aged 7–9 years (n = 395) frommainstream
UK schools. In a randomized controlled trial, we then explored whether 16-
week supplementation (600 mg day1) with algal docosahexaenoic acid
versus placebomight improve sleep in a subset of those children (n = 362)
who were underperforming in reading. In a randomly selected subsample
(n = 43), sleepwas also assessed objectively via actigraphy. In 40%of the
epidemiological sample, Child Sleep Habits Questionnaire scores indi-
cated clinical-level sleep problems. Furthermore, poorer total sleep
disturbance scores were associated weakly but signiﬁcantly with lower
blood docosahexaenoic acid (std coeff. 0.105*) and a lower docosa-
hexaenoic acid : arachidonic acid ratio (std coeff. 0.119**). The treat-
ment trial showed no signiﬁcant effects on subjective sleep measures.
However, in the small actigraphy subsample, docosahexaenoic acid
supplementation ledonaverage to seven fewerwakeepisodesand58 min
more sleep per night. Cautiously, we conclude that higher blood levels of
docosahexaenoic acidmay relate to better child sleep, as rated by parents.
Exploratory pilot objective evidence from actigraphy suggests that doco-
sahexaenoic acid supplementation may improve children’s sleep, but
further investigations are needed.
INTRODUCTION
Numerous studies have found that good sleep is essential for
children’s general health, cognitive functioning and emotional
wellbeing (Ivanhoe et al., 2007; Liu et al., 2012). However,
epidemiological studies indicated that lack of sleep in children
is common in most western countries (Smaldone et al.,
2007). Substantial evidence now links poor sleep with
attention deﬁcit/hyperactivity disorder (ADHD) (Cortese et al.,
2009; Wiggs et al., 2005), as well as with other difﬁculties
with behaviour and learning in children (Dewald et al., 2010;
Kopasz et al., 2010).
Similarly, adequate dietary intakes of omega-3 and omega-
6 fatty acids are fundamental to health, wellbeing and
cognitive performance in both children and adults, as they
and their derivatives are required for the proper structure and
function of almost all cells and systems in the brain and body.
However, most modern, western-type diets are seriously
lacking in the long-chain omega-3 fatty acids [eicosapenta-
enoic acid (EPA) and docosahexaenoic acid (DHA)] that are
most important for physical and mental wellbeing. Deﬁcien-
cies in these omega-3s have been repeatedly implicated
in ADHD and related child behaviour and learning difﬁcul-
ties (Richardson, 2006), and some evidence suggests
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beneﬁts from supplementation with omega-3 fatty acids not
only in these domains (Bloch and Qawasmi, 2011; Tan et al.,
2012), but also for behaviour and cognition in children from
the general school population (Richardson et al., 2012).
Furthermore, very low blood levels of EPA and DHA were
found in a recent study of healthy UK schoolchildren
(Montgomery et al., 2013).
The importance of long-chain polyunsaturated fatty acids
(LC-PUFA) for sleep initiation and maintenance has long
been known (Yehuda et al., 1998). For example, arachidonic
acid (AA) is required as a precursor for the sleep-promoting
prostaglandin D2 (Urade and Hayaishi, 2011), and DHA also
appears essential for sleep regulation (Lavialle et al., 2008).
Evidence suggests that the balance of DHA and AA in the
pineal gland regulates melatonin production (Zaouali-Ajina
et al., 1999), with higher levels of DHA relating to increased
levels of melatonin (Zhang et al., 1998). In the underlying
processes DHA seems needed for one of the enzymes which
transforms serotonin into melatonin (Catala, 2010; Peuhkuri
et al., 2012).
In line with these mechanisms, epidemiological studies ﬁnd
higher levels of omega-3 fatty acids associated with fewer
sleep problems in infants (Cheruku et al., 2002) and adults
(Papandreou, 2013) and children with ADHD (Burgess et al.,
2000). DHA was also associated with less severe sleep
apnea (Ladesich et al., 2011).
Trials among clinical populations suggest that LC-PUFA
supplementation might improve sleep. Treatments including
omega-3 and omega-6 fatty acids with other nutrients
improved sleep quality (Yehuda et al., 2011) and reduced
sleep disorders (Huss et al., 2010) among children with
behavioural problems.
From trials using fatty acids alone, it appears that omega-3
fatty acidsmight bemore effective for sleep problems. A recent
RCT with insomnia patients found little or no beneﬁt from
supplementation with the omega-6 linoleic acid (LA) (Cornu
et al., 2010). In contrast, a trial among pregnant women found
improved sleep patterns in infants born following omega-3
DHA supplementation (Judge et al., 2012).
To date, however, very little is known about the relationship
of LC-PUFA and sleep in healthy children. In addition, given
treatment formulations that combine fatty acids (FA) with other
supplements, current evidence is insufﬁcient to demonstrate
beneﬁts fromDHA supplementation alone for sleep in children.
Objectives
The aims of this study were twofold: (1) to explore associ-
ations between child sleep and biochemical measures of
blood fatty acid status; and (2) to assess the effect of DHA
supplementation on children’s sleep.
Hypotheses
On the basis of the existing literature we predicted that: (1)
higher blood concentrations of long-chain omega-3 fatty
acids would be associated with better child sleep; and (2)
DHA supplementation would lead to improvements in child
sleep.
METHODS
Study design
The Docosahexaenoic Acid (DHA) Oxford Learning and
Behaviour (DOLAB) Study was designed in two stages.
Stage 1 was an epidemiological study of blood fatty acid
status in relation to learning and behaviour. This formed the
screening stage of the subsequent intervention trial. Stage 2
was a double-blind, ﬁxed-dose, parallel-group randomized
controlled trial (RCT) of supplementation with DHA versus
placebo over 16 weeks.
Population
Epidemiological sample – stage 1
Healthy children were invited from Oxfordshire (UK) main-
stream primary schools between January 2009 and Novem-
ber 2010 on the basis of Local Authority data of all children in
the county (Montgomery et al., 2013).
Children from year groups 3, 4 and 5 (typically aged
7–9 years) were eligible if they had no signiﬁcant learning
difﬁculty [i.e. no statement of ‘special educational needs’
(Department of Education, 2001)], but were thought to have
below-average literacy skills according to nationally
standardized assessments at age 7 [Key Stage 1 catego-
ries: 2C, 1 and W (Standards and Testing Agency, 2009)]
or teachers’ current judgements. Children were excluded for
speciﬁc medical disorders (e.g. visual or hearing impair-
ment), ﬁrst language other than English or if schools felt
their social/family circumstances would make inclusion
inappropriate.
Intervention sample – stage 2
From the epidemiological sample in stage 1362 children were
included if they were underperforming in reading (≤33rd-
centile) on age-standardized testing (British Ability Scales II)
but were otherwise healthy, and not taking fatty acid
supplements, nor eating ﬁsh more than twice a week
(Richardson et al., 2012). Children were excluded if taking
any medication thought likely to affect behaviour (e.g.
Ritalin).
A random subsample was drawn from this population for
the objective measurement of sleep using actigraphy.
The inclusion and exclusion criteria reﬂected clinical and
research experience that this age and ability group was most
likely to show signiﬁcant improvements in literacy skills – the
primary outcome – following omega-3 supplementation,
without confounding effects due to medical or behavioural
conditions (Richardson and Montgomery, 2005).
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At neither stage were children selected on the basis of a
sleep problem. Consent for every stage of the study was
obtained in advance. Fig. 1 provides details of the sample.
Sample size
The RCT sample was powered based on the primary
outcome ‘reading ability’, which indicated that 180 partici-
pants per group would provide 90% power with an a of 5%,
for an effect size of r = 0.169 (Cohen’s d = 0.343)
(Richardson et al., 2012).
Randomization
Randomization was conducted by the University of Oxford’s
Centre for Statistics in Medicine, using minimization to
ensure balanced treatment groups for sex and school, and
including a random subsample of children whose sleep was
assessed objectively using actigraphy.
Treatment
Active treatment in stage 2 was a ﬁxed dose of 600 mg day1
of algal DHA, delivered in three 500-mg capsules. Placebo
treatment consisted of three 500-mg capsules per day
containing corn/soybean oil, matchedwith the active treatment
for taste and colour (both treatments were provided by DSM
Nutritional Products, Columbia, MD, USA).
Treatments were dispensed in schools (during school
days) and by parents (during weekends and school holidays),
with instructions that three capsules should be taken daily
with lunch. Parents and schools were given diaries to record
capsule consumption, to encourage compliance and for
monitoring purposes.
Children invited 
n = 1376
Epidemiology sample
(CSHQ and  blood data available)
n = 395
Actigraphy subsample
n = 43 
(randomly selected)
Blood or sleep data not available
(n = 280) of which:
Blood lost in processing (n = 103);
No blood given (n = 79);
CSHQ non-response (n = 98);
Did not meet inclusion criteria (n = 313) of which:
BAS Reading> 33% (n = 236 ); Eating Fish ≥ 2x week (n = 50);
Already taking omega-3 (n = 9);  Sibling in study (n = 8);
Capsule refusal (n = 5);  Moderate Learning Difficulty (n = 3);
Medication (n = 2)
Parents did not consent (n = 701)
Baseline 
(Active n = 17, Placebo n = 24)
Postintervention
(Active n = 15, Placebo n = 19)
Actigraph not 
worn (n = 2)
Parent consent
n = 675
Randomization (RCT)  
sample 
n = 362
Postintervention
Active n = 179, Placebo n = 180
Children moved out of area (n = 3)
Baseline
Active n = 180, Placebo n = 182
Actigraph not 
worn (n = 9)
Figure 1. Flowchart.
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Outcomes: subjective and objective sleep
Sleep was measured subjectively via a parent-report ques-
tionnaire in all children at stage 1, and again postintervention
for children who entered the RCT. In addition, objective sleep
was measured via actigraphy at baseline and postinterven-
tion in a random subsample of the RCT children.
Subjective sleep – Child Sleep Habits Questionnaire (CSHQ)
The CSHQ is a well-validated parent-reported screening
instrument for behaviourally and medically based sleep
problems, designed and validated speciﬁcally for school
children aged 4–10 years (Owens et al., 2000). Parents/
carers are asked to rate their child’s sleeping habits over a
recent typical week on 45 items using a three-point scale
(3 = usually/2 = sometimes/1 = rarely/never). Responses
are scored to derive eight subscales (bedtime resistance;
sleep duration; parasomnias; sleep disturbed breathing; night
wakings; daytime sleepiness; sleep anxiety and sleep onset
delay) and one total sleep disturbance scale.
Post-hoc, we considered children with total CSHQ scores
>41 to beasubgroupwith clinical-level sleep problems (Owens
et al., 2000), i.e. meeting criteria for clinical ‘caseness’.
Objective Sleep – actigraphy and sleep diaries
Sleep duration, wake episodes and latency were recorded for
5 nights pre- and postintervention via actigraphy (MicroMini-
MotionloggerTM, Ambulatory Monitoring Inc., Ardsley, NY,
USA), which has good properties in detecting sleep in
children (Meltzer et al., 2012). To provide sufﬁcient mea-
surement reliability, the following variables are reported as
average times/scores over ﬁve nights (Huang et al., 2011):
• Sleep onset and offset times
• Sleep duration in minutes (total sleep period between
onset and offset)
• Minutes awake between sleep onset and offset
• Sleep efﬁciency (total sleep time divided by time in bed)
• Sleep latency (minutes taken to fall asleep)
• Number of night wakings after sleep onset
Actigraphy data were augmented by parents completing a
sleep diary detailing their child’s bedtime and rising time, any
intervals when the actigraph was removed and their percep-
tion of the child’s periods of sleep.
Blood fatty acid measures
Blood samples were taken by trained researchers via a
ﬁnger-stick method (Bailey-Hall et al., 2008) [also see
Montgomery et al. (2013)]. Blood fatty acid concentrations
were assessed using gas-chromatography of total lipids in
capillary whole blood (Ichihara et al., 2002), expressed as a
weight percentage.
Other measures
Demographic variables
The children’s age, sex, ethnicity and eligibility for free school
meals (FSM) were obtained from Local Authority or school
data, with FSM used as a proxy for socioeconomic status
(SES).
Health status, medication and ﬁsh/supplement consumption
This information was collected by questionnaire from parents/
guardians. In addition, weight was measured at baseline by
researchers.
Statistical methods
Item-missing data on the CSHQ were imputed using the
mean value of the respective subscale. If all observations in
a subscale were missing, although ≥80% of the total
CSHQ had been rated, the imputed value was the mean of
that subscale for the whole sample. For calculating the total
sleep disturbance score the mean of all non-duplicated
items in the subscales were used, in keeping with existing
literature.
The raw actigraphy data, zero-crossing-mode counts,
were scored with the Sadeh algorithm (Sadeh et al., 1994)
using the Action4 software (version 1.16; Ambulatory
Monitoring Inc., Ardsley, NY, USA), which has well-
validated benchmark properties in detecting sleep pat-
terns compared with polysomnography (Tilmanne et al.,
2009).
In the epidemiology sample, associations were examined
with Spearman’s rank correlations, accounting for distribu-
tional problems, and with ordinary least squares (OLS)
regressions with bootstrapped standard errors controlling
for demographic differences.
In the intervention sample, group differences in change-
scores (postintervention minus baseline scores) were anal-
ysed using independent t-tests or Wilcoxon’s rank sum tests,
depending on the normality of the data (Shapiro–Wilks).
These analyses were conducted on an intention-to-treat
principle (ITT), i.e. including all children randomized, using
mean imputation. Post-hoc subgroup analyses were also
conducted on children for whom parent-ratings indicated
clinical sleep problems at baseline.
All analyses were conducted in Stata version 11.2 (Stata-
Corp., College Station, TX, USA). The syntax used is
available on request.
Ethics
The study was approved by the Milton Keynes NHS
Research Ethics Committee (08/H0603/49). Written informed
consent was gained from parents/carers and verbal assent
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from the children, prior to initial screening. Trial protocol and
the Consolidated Standards Of Reporting Trials (CONSORT)
checklist are available at: Protocol: doi: 10.1371/journal.
pone.0043909.s001; Checklist: doi: 10.1371/journal.pone.
0043909.s002. The trial was registered with ClinicalTrials.
gov (NCT01066182) and Controlled-Trials.com (ISRCTN
99771026).
RESULTS
Samples
Epidemiological sample – stage 1
Parents of 675 children attending 74 Oxfordshire schools
consented to their child’s participation (see Fig. 1). Blood
samples were provided by 596 children, although 103 of
these samples were either too small or were lost in the
chemical preparation process. Overall, blood data from 493
children were available for analysis. Further, missing data on
the subjective sleep measure meant that both blood and
sleep data were available for 395 children.
Intervention sample – stage 2
A total of 362 of the children in stage 1 met inclusion criteria
to take part in the randomized controlled trial assessing the
effects of 16 weeks’ supplementation with 600 mg day1 of
DHA or placebo.
Actigraphy subsample
It was only possible to justify this objective assessment on a
random subset of children from the treatment trial, given
resource constraints and the demands that actigraphy places
on children and parents. Forty-three children took part in this
exploratory pilot study.
Post-hoc subgroup with sleep problems
A total of 188 children were identiﬁed whose parent-rated
sleep at baseline suggested sleep problems (CSHQ total
sleep disturbance score >41). Additional post-hoc subgroup
analyses on an ITT basis were carried out on these children
for their potential clinical relevance.
Sample characteristics – demographics
Table 1 reports the demographic characteristics of the
epidemiology sample (n = 395), the RCT sample (n = 362),
the actigraphy sample (n = 43) and the RCT subgroup of
children with sleep problems (CSHQ total sleep disturbance
score >41, n = 188, includes imputation). The samples were
compared for any differences in their demographic make-up.
Some signiﬁcant differences were found, largely reﬂecting
the differing entry criteria for the RCT versus the epidemio-
logical study (see Appendix 1, Table 7). For example, fewer
parents of low-income families gave consent to their child
taking part in the study at all. However, proportionally more
Table 1 Demographic characteristics of the samples analysed
Epidemiology sample
(CSHQ and blood data
available, n = 395)
RCT sample
(n = 362)
Actigraphy
sample
(n = 43)
CSHQ caseness*
subgroup of RCT
(n = 188)
Sex, n (%)
Female 177 (44.81) 170 (46.96) 21 (48.84) 99 (52.38)
Male 218 (55.19) 192 (53.04) 22 (51.16) 89 (47.09)
Age in years, n (%)
6/7 years 111 (28.1) 80 (22.1) 9 (20.93) 39 (20.63)
8 years 143 (36.2) 137 (37.85) 18 (41.86) 69 (36.51)
9/10 years 141 (35.7) 145 (40.06) 16 (37.21) 80 (42.33)
Weight, kg
Mean (SD) 30.72 kg (7.68) 30.86 kg (7.54) 33.12 kg (8.24) 30.72 kg (7.48)
Free school meals, n (%)
Not eligible 347 (87.85) 289 (79.83) 32 (74.42) 138 (73.02)
Eligible 48 (12.15) 73 (20.17) 11 (25.58) 50 (26.46)
Ethnicity, n (%)
White 362 (91.65) 330 (91.16) 41 (95.35) 171 (90.48)
Mixed 12 (3.04) 16 (4.42) 1 (2.33) 8 (4.23)
Asian 6 (1.52) 2 (0.55) 0 (0) 2 (1.06)
Black 1 (0.25) 1 (0.28) 0 (0) 1 (0.53)
Other 5 (1.27) 7 (1.93) 1 (2.33) 3 (1.59)
Missing
information
9 (2.28) 6 (1.8) 0 (0) 3 (1.59)
RCT, randomized clinical trial; SD, standard deviation; CSHQ, Child Sleep Habits Questionnaire.
*‘Caseness’: clinical level sleep problems as indicated by total CSHQ score >41.
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such children were eligible for the RCT owing to their poor
reading ability.
The signiﬁcant differences relating to sleep problems
appear when contrasting the subgroup of children with a
CSHQ total of >41 with the overall RCT sample. This
subgroup contains signiﬁcantly more girls (v2 = 5.10,
P < 0.023) and more children with free school meal
entitlement (v2 = 11.42, P < 0.002). Furthermore, the actig-
raphy subsample had a higher average weight than the RCT
sample (t = 2.08, P < 0.038).
Epidemiological results (n = 395)
Subjective sleep
Parent-rated sleep quality as measured by the CSHQ was
found to be poor. The average score of the total sleep
disturbance scale was 41.05 [standard deviation
(SD = 6.98] and ranged up to 69 (Fig. 2). Almost 41%
(n = 161) of the children had a total sleep disturbance
score above the cut-off for clinical caseness (see Appen-
dix 2, Table 8).
Fatty acid concentrations
The average DHA (22 : 6, n-3) concentration was 1.93%
(SD = 0.54) and total omega-3 fatty acids were 4.11%
(SD = 0.85) in the epidemiological sample (for full results
see Appendix 3, Table 9). As discussed elsewhere, this is
low from a health perspective (Montgomery et al., 2013).
Relationships between subjective sleep and fatty acids
The associations between blood fatty acid concentrations
and subjective measures of sleep are reported in Table 2.
DHA was related signiﬁcantly and negatively to the total
sleep disturbance score (q = 0.131, P < 0.009), bedtime
resistance (q = 0.113, P < 0.025) and parasomnias
(q = 0.106, P < 0.035). The ‘Omega-3 index’
(EPA + DHA) was correlated negatively with bedtime
resistance (q = 0.109, P < 0.031). The DHA : AA ratio
was associated signiﬁcantly and negatively with the total
sleep disturbance score (q = 0.133, P < 0.008). Concen-
trations of total omega-3 were correlated negatively with
scores on the sleep duration subscale (q = 0.103,
P < 0.04).
Subjective sleep and fatty acids – controlling for demographic
differences
In Table 3 we report the associations between subjective
sleep and blood fatty acids, while controlling for demographic
differences between the children in terms of age, gender,
weight and SES. Consistent with the uncontrolled correlation
results we found that:
• DHA was related signiﬁcantly and negatively with the total
sleep disturbance score (std coeff. 0.105, P < 0.026);
and
• The DHA : AA ratio had a signiﬁcant and negative asso-
ciation with the total sleep disturbance score (std coeff.
0.119, P < 0.009).
The other correlations were not robust in the light of
demographic differences in the sample. However, additional
signiﬁcant relationships after controlling for these differences
were found for the DHA : AA ratio with bedtime resistance
(std coeff. 0.09, P < 0.018) and sleep duration (std coeff.
0.1, P < 0.018).
Contrary to expectations, positive relationships were found
for DPA (n-3) and parasomnias (std coeff. 0.107, P < 0.043),
EPA and parasomnias (std coeff. 0.163, P < 0.007) and the
EPA : AA ratio and parasomnias (std coeff. 0.162,
P < 0.007). Additionally, the short-chain omega-3 ALA was
associated positively with sleep anxiety (0.114, P < 0.047;
for full regression results see Appendix 5, Tables 11–19).
RCT results (n = 362)
Tables 4 and 5 report the baseline and postintervention
means, change scores and statistical test results for group
differences for both the subjective and objective sleep
measures on an ITT basis.
DHA supplementation and changes in subjective sleep
During the 16-week intervention, slight but non-signiﬁcant
improvements were seen in both groups for all but one CSHQ
subscale (sleep duration).
DHA supplementation and changes in objective sleep
Actigraphy results showed that total sleep duration increased
by 58 min more in the active group than in controls
–1 SD +1 SD
Mean
41.06
Potentially Clinical Sleep Problems
Total Disturbance Score>41 (n = 161)
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Figure 2. Child Sleep Habits Questionnaire (CSHQ) total sleep
disturbance distribution in the epidemiology sample.
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(P < 0.029; Fig. 3). Correspondingly, the reduction in wake
episodes was signiﬁcantly greater in children on active
treatment (seven fewer wake episodes per night, P < 0.013).
With the less conservative alpha-level applied for explor-
atory analyses, group differences were also evident for
changes in min awake (active versus placebo: 44 min,
P < 0.068) and overall sleep efﬁciency (+8%, P < 0.052).
Post-hoc RCT subgroup results for children with clinical
sleep problems (n = 188)
DHA supplementation and changes in subjective sleep
Approximately 52% (188) of the RCT children were found to
have clinical-level sleep problems at baseline, i.e. CSHQ total
sleep disturbance score >41 (see Appendix 2, Table 8).
Table 6 shows the effects of treatment on CSHQ scores in
this post-hoc subgroup. Ratings on the parasomnias sub-
scale fell signiﬁcantly more in the active treatment group than
controls (P < 0.039), as did total sleep disturbance
(P < 0.049).
DHA supplementation and changes in objective sleep
The sample size for the subgroup of children with clinical-
level sleep problems for which actigraphy results are avail-
able is very small (active = 11, placebo = 9). The analyses
for this subgroup did not detect any signiﬁcant changes
following the intervention (see Appendix 4, Table 10).
DISCUSSION
To the authors’ knowledge, this is the ﬁrst published study
investigating associations between LC-PUFA status and
sleep, and the effect of DHA supplementation on sleep, in
healthy children. This sample was selected for below-
average reading at age 7, but had no medical diagnoses or
learning disabilities. Previous research has demonstrated
clear links between children’s sleep and their physiological,
mental and emotional health as well as their cognition and
behaviour (Dewald et al., 2010; Ivanhoe et al., 2007; Liu
et al., 2012). Similarly, existing evidence points to associa-
tions between children’s omega-3 LC-PUFA status and their
cognition, as well as their behaviour.
In terms of the objectives of this study, our main ﬁndings
are as follows:
• In this large epidemiological sample of healthy children:
• Forty per cent of these children appear to have a clinical-
level sleep problem, as deﬁned by the cut-off for clinical
caseness on the CSHQ. This is consistent with other
ﬁndings for the general child population in the United
States and Europe (Smaldone et al., 2007).
• Higher blood DHA status was associated signiﬁcantly
with better sleep (std coeff.: 0.105, P < 0.026), as
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assessed by the total sleep disturbance scores from the
CSHQ even when controlling for demographic variables.
Correspondingly, associations between the DHA : AA
ratio and total sleep disturbance score were found to be
signiﬁcant (std coeff.: 0.119, P < 0.009).
• No consistent associations were found between CSHQ
scores and other fatty acids when controlling for demo-
graphic variables.
• In the subsequent RCT of supplementation with DHA:
• The pilot actigraphy subsample results indicated signif-
icant group differences in children’s sleep following a 16-
week treatment with 600 mg day1 of DHA. Sleep
duration improved by 58 min more in children receiving
active treatment versus placebo, with fewer and shorter
night-wakings and corresponding improvement in sleep
efﬁciency.
• No signiﬁcant effects of supplementation were evident
on the subjective sleep measures for the whole sample.
However, in a post-hoc subgroup with clinical-level sleep
problems, DHA treatment did improve total sleep distur-
bance scores (Z = 1.963, P < 0.05).
STRENGTHS AND LIMITATIONS
The ﬁndings presented in this paper should be interpreted
cautiously, for a number of reasons. First, the epidemiological
analysis ﬁnds relatively few statistically signiﬁcant results in
view of the number of relationships tested. While Bonferroni
corrections would be inappropriate (owing to the strong
intercorrelations always found between individual blood fatty
acid values), further studies are warranted to conﬁrm the
inverse association observed here between blood DHA
status and subjective sleep problems. In order to distinguish
individual differences more clearly, these studies should also
collect a wider range of demographic variables associated
with sleep outcomes, such as waist circumference.
Secondly, the results from the intervention study must be
regarded as very preliminary, as beneﬁts of DHA supple-
mentation were found only for objective measures of sleep,
and these were available only for a small subset of the RCT
sample.
Thirdly, it is important to emphasize that the children in the
study were not selected for sleep problems, hence these
results cannot be assumed to generalize to a clinically
referred population. Conversely, the fact that this was a
general school population sample, with 60% of children not
reported to have clinical-level sleep problems at baseline,
makes it all the more impressive that any treatment effects
were detected.
Fourthly, there were inevitably some missing data, which
always requires some caution in the interpretation of ﬁndings.
In the RCT, around 20% of children had missing data for one
or other of the sleep measures postintervention, which is
broadly in line with other studies (see, for example, Price
et al., 2012).
A major strength of this study is its large, non-clinical
sample of children, broadly representative of the more
general population of UK children aged 7–9 years. Another
strength is the use of ﬁngerstick blood samples, allowing
objective measurement of blood fatty acid status. In addition,
sleep was assessed both subjectively (via a well-validated
and age-standardized parent rating scale) in the whole
sample and objectively (via actigraphy) in a subset.
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IMPLICATIONS
The improvements in sleep found in this study may be both
clinically important and comparable to the improvements
achieved by current front-line interventions for child sleep
problems (Edinger et al., 2001; Weiss et al., 2006). These
kinds of improvements could, if replicated, be expected to
lead to signiﬁcant beneﬁts in physical health, mood, behav-
iour and cognition, including educational achievement.
Indeed, improvements in both behaviour and learning were
found in the DOLAB RCT (Richardson et al., 2012).
While the actigraphy can only provide simple measures of
sleep duration and timing, it seems likely that the changes
observed here would normally be accompanied by qualitative
improvements in sleep architecture. Further studies using
polysomnography would, of course, be needed to elucidate
potential mechanisms.
These results are in line with the existing literature, as there
are already some reports of associations between poor sleep
outcomes and low blood concentrations of omega-3 LC-
PUFA (Papandreou, 2013; Stevens et al., 1995), as well as
some preliminary research indicating beneﬁts for sleep from
fatty acid supplementation in children with behavioural
problems (Yehuda et al., 2011).
Importantly, these ﬁndings also ﬁt well with theoretical
mechanisms, as DHA is the main omega-3 found in the brain
and fatty acids are involved in sleep regulation via melatonin
metabolism (Lavialle et al., 2008), with increased DHA : AA
ratios related directly to the increased secretion of melatonin
(Peuhkuri et al., 2012). This provides a potential physiolog-
ical explanation for our ﬁnding that DHA supplementation
improves sleep continuity and duration.
As noted earlier, the epidemiology sample broadly
matched the wider population of children in the United
Kingdom, giving good reason to believe that the association
found here between low blood DHA and sleep problems
would be generalizable. By contrast, the RCT sample
involved those children who were underperforming in reading
(<33rd-centile), hence generalizability to the wider UK pop-
ulation cannot be assumed.
However, the treatment effect observed in the pilot actig-
raphy for these children was substantial, at almost 1 h of
extra sleep per night on objective measurement. The phys-
ical, mental and social beneﬁts that would be expected to
follow from such an improvement are profound. In the post-
hoc subgroup with sleep problems (CSHQ > 41), the effects
on the subjective total sleep disturbance score appear to be
positive and in line with the actigraphy results. This is
suggestive that future work in a clinical sample of children
with sleep problems would be justiﬁed.
CONCLUSION
DHA supplementation has long been shown to be safe and
well-tolerated, as we have already conﬁrmed in this sample
(Richardson et al., 2012). Furthermore, we also found very
low blood levels of this key fatty acid in a larger sample of
healthy UK schoolchildren, indicating that omega-3 deﬁcien-
cies are widespread in the general population (Montgomery
et al., 2013). For these reasons, further investigations of the
effects of this simple nutritional intervention on child sleep are
needed, ideally in both clinical and general populations.
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APPENDIX 2 CSHQ SCORES AND ‘CLINICAL CASENESS ’ IN THE EPIDEMIOLOGY SAMPLE
APPENDIX 3 FATTY ACID LEVELS IN THE CSHQ EPIDEMIOLOGY SAMPLE
Table 8 Descriptive values for the CSHQ subscales in the DOLAB study
CSHQ epidemiology sample CSHQ caseness subgroup†
Mean SD Range Mean SD Range
Bedtime resistance 7.11 1.95 6–17 8.05 2.22 6–17
Sleep onset delay 1.66 0.79 1–3 1.91 0.69 1–3
Sleep duration 3.84 1.34 3–9 4.4 1.33 3–9
Sleep anxiety 5.18 1.54 4–12 5.75 1.55 4–11
Night wakings 3.66 1.13 3–9 3.96 1.08 3–9
Parasomnias 8.72 1.96 7–17 9.36 1.84 7–17
Sleep disturbed breathing 3.44 0.92 3–9 3.77 1.04 3–9
Daytime sleepiness 9.77 3.04 6–20 11.24 2.7 6–19
Total sleep disturbance 41.05 6.98 31–69 45.8 5.65 41.34–67
†CSHQ total sleep disturbance >41 n = 395 n = 161
CSHQ, Child Sleep Habits Questionnaire; SD, standard deviation; DOLAB, Docosahexaenoic Acid (DHA) Oxford Learning and Behaviour
Study.
Table 9 Blood fatty acid levels in the CSHQ epidemiology sample
Mean SD Range
DHA (22 : 6) 1.93 0.54 0.9–3.8
DPA (22 : 5) 1.03 0.28 0.53–3.62
EPA (20 : 5) 0.56 0.21 0–2.03
ALA (18 : 3) 0.55 0.26 0–2.32
Total omega-3 4.11 0.85 2.19–8.01
DPA (n-6) (22 : 5) 0.25 0.1 0–0.63
Adrenic (22 : 4) 1.10 0.22 0.42–1.81
AA (20 : 4) 8.18 1.31 4.3–11.73
DGLA (20 : 3) 1.55 0.34 0.81–2.9
GLA (18 : 3) 0.32 0.24 0–1.41
LA (18 : 2) 19.22 2.33 12.66–26.08
Total omega-6 30.88 3.33 20.61–39.79
Omega-3 index 2.49 0.67 1.26–5.24
Ratio DHA : AA 0.24 0.06 0.14–0.53
Ratio EPA : AA 0.07 0.03 0–0.24
n = 395
CSHQ, Child Sleep Habits Questionnaire; SD, standard deviation; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapen-
taenoic acid (both omega-3 and omega-6); DHA, docosahexaenoic acid; LA, linoleic acid; GLA, gamma-linolenic acid; DGLA, dihomo-
gamma-linolenic acid; AA, arachidonic acid.
ª 2014 The Authors. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.
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